{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:42:04Z","timestamp":1783575724064,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004854","name":"St. Antonius Ziekenhuis","doi-asserted-by":"publisher","award":["17.4"],"award-info":[{"award-number":["17.4"]}],"id":[{"id":"10.13039\/501100004854","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Catharina Hospital Eindhoven","award":["2017-5"],"award-info":[{"award-number":["2017-5"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>CRC-PIPAC prospectively assessed repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) as a palliative monotherapy (i.e., without concomitant systemic therapy in between subsequent procedures) for unresectable colorectal peritoneal metastases (CPM). The present study explored patient-reported outcomes (PROs) during trial treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this single-arm phase 2 trial in two tertiary centers, patients with isolated unresectable CPM received 6-weekly PIPAC-OX (92\u00a0mg\/m<jats:sup>2<\/jats:sup>). PROs (calculated from EQ-5D-5L, and EORTC QLQ-C30 and QLQ-CR29) were compared between baseline and 1 and 4 weeks after the first three procedures using linear mixed modeling with determination of clinical relevance (Cohen\u2019s <jats:italic>D<\/jats:italic>\u2009\u2265\u20090.50) of statistically significant differences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty patients underwent 59 procedures (median 3 [range 1\u20136]). Several PROs solely worsened 1 week after the first procedure (index value \u2212\u20090.10, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; physical functioning \u2212\u200920, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; role functioning \u2212\u200927, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; social functioning \u2212\u200918, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; C30 summary score \u2212\u200916, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; appetite loss\u2009+\u200915, <jats:italic>p<\/jats:italic>\u2009=\u20090.007; diarrhea\u2009+\u200915, <jats:italic>p<\/jats:italic>\u2009=\u20090.002; urinary frequency\u2009+\u200913, <jats:italic>p<\/jats:italic>\u2009=\u20090.004; flatulence\u2009+\u200913, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). These PROs returned to baseline at subsequent time points. Other PROs worsened 1 week after the first procedure (fatigue\u2009+\u200923, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; pain\u2009+\u200929, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; abdominal pain\u2009+\u200932, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), second procedure (fatigue\u2009+\u200920, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; pain\u2009+\u200921, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; abdominal pain\u2009+\u200920, <jats:italic>p<\/jats:italic>\u2009=\u20090.002), and third procedure (pain\u2009+\u200922, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; abdominal pain\u2009+\u200922, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Except for appetite loss, all changes were clinically relevant. All analyzed PROs returned to baseline 4 weeks after the third procedure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients receiving repetitive PIPAC-OX monotherapy for unresectable CPM had clinically relevant but reversible worsening of several PROs, mainly 1 week after the first procedure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov: NCT03246321; Netherlands trial register: NL6426.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00464-021-08802-6","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T16:51:17Z","timestamp":1636563077000},"page":"4486-4498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC)"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-0994","authenticated-orcid":false,"given":"Robin J.","family":"Lurvink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen P.","family":"Rovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C. E.","family":"Wassenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Checca","family":"Bakkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus W. A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan M.","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floortje","family":"Mols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus J.","family":"Wiezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon W.","family":"Nienhuijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H. J. T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"8802_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","volume":"32","author":"LG van der Geest","year":"2015","unstructured":"van der Geest LG, Lam-Boer J, Koopman M et al (2015) Nationwide trends in incidence, treatment, and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis 32:457\u2013465","journal-title":"Clin Exp Metastasis"},{"issue":"20","key":"8802_CR2","first-page":"31031","volume":"S0748\u20137983","author":"RJ Lurvink","year":"2020","unstructured":"Lurvink RJ, Bakkers C, Rijken A et al (2020) Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study. Eur J Surg Oncol S0748\u20137983(20):31031\u201331033","journal-title":"Eur J Surg Oncol"},{"key":"8802_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2016.07.002","volume":"65","author":"LG Razenberg","year":"2016","unstructured":"Razenberg LG, Lemmens VE, Verwaal VJ et al (2016) Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a population-based study. Eur J Cancer 65:113\u2013120","journal-title":"Eur J Cancer"},{"key":"8802_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/DCR.0000000000000412","volume":"58","author":"P Quere","year":"2015","unstructured":"Quere P, Facy O, Manfredi S et al (2015) Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum 58:743\u2013752","journal-title":"Dis Colon Rectum"},{"key":"8802_CR5","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1\u201311","journal-title":"Cancer Treat Rep"},{"key":"8802_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","volume":"89","author":"RL Dedrick","year":"1997","unstructured":"Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89:480\u2013487","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"8802_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4(5):277\u2013283","journal-title":"Lancet Oncol"},{"key":"8802_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","volume":"26","author":"W Solass","year":"2012","unstructured":"Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA (2012) Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 26:1849\u20131855","journal-title":"Surg Endosc"},{"key":"8802_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","volume":"26","author":"W Solass","year":"2012","unstructured":"Solass W, Herbette A, Schwarz T et al (2012) Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc 26:847\u2013852","journal-title":"Surg Endosc"},{"key":"8802_CR10","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","volume":"20","author":"A Blanco","year":"2013","unstructured":"Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA (2013) Renal land hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 20:2311\u20132316","journal-title":"Ann Surg Oncol"},{"key":"8802_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T et al (2014) Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21:553\u2013559","journal-title":"Ann Surg Oncol"},{"key":"8802_CR12","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F et al (2019) Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20:e368\u2013e377","journal-title":"Lancet Oncol"},{"issue":"1","key":"8802_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejso.2020.08.020","volume":"47","author":"O Sgarbura","year":"2021","unstructured":"Sgarbura O, Villeneuve L, Alyami M et al (2021) Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): still standardized or on the verge of diversification? Eur J Surg Oncol 47(1):149\u2013156","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"8802_CR14","doi-asserted-by":"publisher","first-page":"e030408","DOI":"10.1136\/bmjopen-2019-030408","volume":"9","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Lurvink RJ, Wassenaar EC et al (2019) Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC). BMJ Open 9(7):e030408","journal-title":"BMJ Open"},{"key":"8802_CR15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09558-4","author":"KP Rovers","year":"2021","unstructured":"Rovers KP, Wassenaar EC, Lurvink RJ et al (2021) Pressurized Intraperitoneal Aerosol Chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-020-09558-4","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"8802_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM et al (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13(2):267\u2013272","journal-title":"Ann Oncol"},{"key":"8802_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136\u2013147","journal-title":"J Clin Oncol"},{"issue":"2","key":"8802_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1515\/pp-2016-0005","volume":"1","author":"M Reymond","year":"2016","unstructured":"Reymond M, Demtr\u00f6der C, Solass W, Winnekendonk G, Tempfer C (2016) Electrostatic precipitation pressurized intraperitoneal aerosol chemotherapy (ePIPAC): first in-human application. Pleura Peritoneum 1(2):109\u2013116","journal-title":"Pleura Peritoneum"},{"issue":"Suppl 5","key":"8802_CR19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1245\/s10434-016-5108-4","volume":"23","author":"T Kakchekeeva","year":"2016","unstructured":"Kakchekeeva T, Demtr\u00f6der C, Herath NI et al (2016) In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol 23(Suppl 5):592\u2013598","journal-title":"Ann Surg Oncol"},{"key":"8802_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"8802_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736","journal-title":"Qual Life Res"},{"key":"8802_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"8802_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s11136-015-1210-5","volume":"25","author":"AM Stiggelbout","year":"2016","unstructured":"Stiggelbout AM, Kunneman M, Baas-Thijssen MC et al (2016) The EORTC QLQ-CR29 quality of life questionnaire for colorectal cancer: validation of the Dutch version. Qual Life Res 25:1853\u20131858","journal-title":"Qual Life Res"},{"key":"8802_CR24","unstructured":"EuroQol Research Foundation. EQ-5D-5L User Guide, 2019."},{"key":"8802_CR25","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). European Organisation for Research and Treatment of Cancer, Brussels, 2001."},{"key":"8802_CR26","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/j.ejca.2009.08.014","volume":"45","author":"RN Whistance","year":"2009","unstructured":"Whistance RN, Conroy T, Chie W et al (2009) Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life. Eur J Cancer 45:3017\u20133026","journal-title":"Eur J Cancer"},{"key":"8802_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS et al (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15:708\u2013715","journal-title":"Value Health"},{"key":"8802_CR28","first-page":"582","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41:582\u2013592","journal-title":"Med Care"},{"issue":"11","key":"8802_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","volume":"48","author":"K Cocks","year":"2012","unstructured":"Cocks K, King MT, Velikova G et al (2012) Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30. Eur J Cancer 48(11):1713\u20131721","journal-title":"Eur J Cancer"},{"issue":"1","key":"8802_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 16(1):139\u2013144","journal-title":"J Clin Oncol"},{"key":"8802_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D (2007) Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5:70","journal-title":"Health Qual Life Outcomes"},{"key":"8802_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","volume":"137","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB, Winnekendonk G, Solass W et al (2015) Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol 137:223\u2013228","journal-title":"Gynecol Oncol"},{"key":"8802_CR33","first-page":"6723","volume":"35","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB, Rezniczek GA, Ende P, Solass W, Reymond MA (2015) Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: a cohort study. Anticancer Res 35:6723\u20136729","journal-title":"Anticancer Res"},{"key":"8802_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.5230\/jgc.2018.18.e37","volume":"18","author":"I Gockel","year":"2018","unstructured":"Gockel I, Jansen-Winkeln B, Haase L et al (2018) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): results of a single-center experience and register study. J Gastric Cancer 18:379\u2013391","journal-title":"J Gastric Cancer"},{"key":"8802_CR35","doi-asserted-by":"publisher","first-page":"175883591984640","DOI":"10.1177\/1758835919846402","volume":"11","author":"F Struller","year":"2019","unstructured":"Struller F, Horvath P, Solass W et al (2019) Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol 11:1758835919846402","journal-title":"Ther Adv Med Oncol"},{"key":"8802_CR36","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12885-018-4363-0","volume":"18","author":"U Giger-Pabst","year":"2018","unstructured":"Giger-Pabst U, Demtr\u00f6der C, Falkenstein TA et al (2018) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer 18:442","journal-title":"BMC Cancer"},{"key":"8802_CR37","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1186\/s12885-020-07627-1","volume":"20","author":"GA Rezniczek","year":"2020","unstructured":"Rezniczek GA, Giger-Pabst U, Thaher O et al (2020) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer. BMC Cancer 20:1122","journal-title":"BMC Cancer"},{"key":"8802_CR38","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","volume":"41","author":"K Odendahl","year":"2015","unstructured":"Odendahl K, Solass W, Demtr\u00f6der C et al (2015) Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol 41:1379\u20131385","journal-title":"Eur J Surg Oncol"},{"key":"8802_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","volume":"14","author":"M Robella","year":"2016","unstructured":"Robella M, Vaira M, de Simone M (2016) Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol 14:128","journal-title":"World J Surg Oncol"},{"key":"8802_CR40","doi-asserted-by":"publisher","first-page":"4596176","DOI":"10.1155\/2017\/4596176","volume":"2017","author":"H Teixeira Farinha","year":"2017","unstructured":"Teixeira Farinha H, Grass F, Kefleyesus A et al (2017) Impact of pressurized intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract 2017:4596176","journal-title":"Gastroenterol Res Pract"},{"key":"8802_CR41","doi-asserted-by":"publisher","first-page":"175883591877703","DOI":"10.1177\/1758835918777036","volume":"10","author":"M Graversen","year":"2018","unstructured":"Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB (2018) Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol 10:1758835918777036","journal-title":"Ther Adv Med Oncol"},{"key":"8802_CR42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/biomedicines8050102","volume":"8","author":"M de Simone","year":"2020","unstructured":"de Simone M, Vaira M, Argenziano M et al (2020) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal carcinomatosis: an open-label, single-arm, phase II clinical trial. Biomedicines 8:102","journal-title":"Biomedicines"},{"key":"8802_CR43","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-093320-6","author":"A Taibi","year":"2020","unstructured":"Taibi A, Teixeira Farinha H, Durand Fontanier S, Sayedalamin Z, H\u00fcbner M, Sgarbura O (2020) Pressurized intraperitoneal aerosol chemotherapy enhanced by electrostatic precipitation (ePIPAC) for patients with peritoneal metastases. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-020-093320-6","journal-title":"Ann Surg Oncol"},{"key":"8802_CR44","doi-asserted-by":"publisher","DOI":"10.1245\/s\/10434-020-09508-0","author":"N Tabchouri","year":"2021","unstructured":"Tabchouri N, Buggisch J, Demtroder CR et al (2021) Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s\/10434-020-09508-0","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"8802_CR45","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.ejso.2018.02.012","volume":"44","author":"PH Cashin","year":"2018","unstructured":"Cashin PH, Mahteme H, Syk I, Fr\u00f6din JE, Glimelius B, Graf W (2018) Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases. Eur J Surg Oncol 44(7):983\u2013990","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"8802_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","volume":"22","author":"T Andre","year":"2021","unstructured":"Andre T, Amonkar M, Norquist JM et al (2021) Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (Keynote-177): an open-label, randomised, phase 3 trial. Lancet Oncol 22(5):665\u2013677","journal-title":"Lancet Oncol"},{"issue":"3","key":"8802_CR47","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1245\/s10434-019-08064-6","volume":"27","author":"O Moaven","year":"2020","unstructured":"Moaven O, Votanopoulos KI, Shen P et al (2020) Health-related quality of life after cytoreductive surgery\/HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin. Ann Surg Oncol 27(3):772\u2013780","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"8802_CR48","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ejso.2019.05.007","volume":"45","author":"O Sgarbura","year":"2019","unstructured":"Sgarbura O, H\u00fcbner M, Alyami M et al (2019) Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol 45(12):2386\u20132391","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"8802_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7150\/jca.21460","volume":"9","author":"H Teixeira Farinha","year":"2018","unstructured":"Teixeira Farinha H, Grass F, Labga I, Pache B, Demartines N, H\u00fcbner M (2018) Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy. J Cancer 9(1):13\u201320","journal-title":"J Cancer"},{"issue":"4","key":"8802_CR50","doi-asserted-by":"publisher","first-page":"20180128","DOI":"10.1515\/pp-2018-0128","volume":"3","author":"M Graversen","year":"2018","unstructured":"Graversen M, Lundell L, Fristrup C, Pfeiffer P, Mortensen MB (2018) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an outpatient procedure. Pleura Peritoneum 3(4):20180128","journal-title":"Pleura Peritoneum"},{"key":"8802_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1245\/s10434-020-08743-9","volume":"28","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Tajzai R, Rovers KP et al (2021) Systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases in the CRC-PIPAC trial. Ann Surg Oncol 28:265\u2013272","journal-title":"Ann Surg Oncol"},{"key":"8802_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2020.09.010","volume":"140","author":"F Dumont","year":"2020","unstructured":"Dumont F, Passot C, Raoul JL et al (2020) A phase I dose-escalation study of oxaliplatin delivered via a laparosocpic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peirtoneal metastases of gastrointestintal tract cancers. Eur J Cancer 140:37\u201344","journal-title":"Eur J Cancer"},{"key":"8802_CR53","doi-asserted-by":"publisher","first-page":"e044811","DOI":"10.1136\/bmjopen-2020-044811","volume":"11","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Rauwerdink P, Rovers KP et al (2021) First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phasde II study (CRC-PIPAC-II). BMJ Open 11:e044811","journal-title":"BMJ Open"},{"key":"8802_CR54","doi-asserted-by":"publisher","first-page":"20180118","DOI":"10.1515\/pp-2018-0118","volume":"3","author":"G Kim","year":"2018","unstructured":"Kim G, Tan HL, Chen E et al (2018) Study protocol: phase 1 dose escalating study of pressurized intra-peritoneal aerosol chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis. Pleura Peritoneum 3:20180118","journal-title":"Pleura Peritoneum"},{"key":"8802_CR55","first-page":"20180108","volume":"3","author":"M Graversen","year":"2018","unstructured":"Graversen M, Detlefsen S, Asmussen J et al (2018) Treatment of peritoneal carcinomatosis with pressurized intraperitoneal aerosol chemotherapy: PIPAC-OPC2. Pleura Peritoneum 3:20180108","journal-title":"Pleura Peritoneum"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-021-08802-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-021-08802-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-021-08802-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T17:44:56Z","timestamp":1652118296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-021-08802-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["8802"],"URL":"https:\/\/doi.org\/10.1007\/s00464-021-08802-6","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robin J. Lurvink, Koen P. Rovers, Emma C.E. Wassenaar, Checca Bakkers, Jacobus W.A. Burger, Geert-Jan M. Creemers, Maartje Los, Floortje Mols, Marinus J. Wiezer, Simon W. Nienhuijs, and Djamila Boerma have no conflicts of interest or financial ties to disclose. Ignace H.J.T. de Hingh: an unrestricted research grant outside the submitted work from RanD\/QPS and Roche, paid to the institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}